Media Thread, page-14065

Today, our CEO & MD Leslie Chong met with the esteemed Dr. Yuman Fong at City of Hope to discuss the future of cancer treatment.

Reflecting on Leslie Chong's latest 25 minute Bell Potter presentation which focused on and prioritized azer-cel and onCARlytics (CF33-CD19).

IMO their meeting at City of Hope discussed the following :-

1. Discussed the establishment of the pre-clinical studies combining azer-cel with Imugene’s onCARlytics (CF33-CD19). - data to be submitted to FDA.

2. Discussed the progress of the The Phase 1 OASIS trial (is a world-first) in combining onCARlytics (a CD19-expressing oncolytic virus) with CD19 targeted therapy (blinatumomab, Blincyto®), which is an immunotherapy (antibody) that helps fight acute lymphoblastic leukemia (ALL)
3 sites (City of Hope, University of Cincinnati and MD Anderson Cancer Center) are
currently open in the US with the potential to open a total of 10 sites to recruit
approximately 40-45 patients with advanced solid tumors

3. Discussed the progress of azer-cel: Allogeneic CAR T cell therapy - Currently recruiting Phase 1b trial in patients with diffuse large B cell lymphoma (DLBCL) who relapsed following autologous CAR T therapy.

4. Discussed the progress of the Phase 1 MAST trial assesses the safety and efficacy of VAXINIA administered alone, or in combination with pembrolizumab and dosed both intravenously (IV) or
intratumourally (IT) in a dose escalation study

5. Discussed the establishment of the Phase 1 MAST trial - Bile tract cancer expansion trial opened and is expected to enroll one patient in 10 sites (8 sites in the US and 2 sites in Australia), a total of 10 patients.

Wow,two brilliant minds discussing IMU's future cancer treatments at The City of Hope!.

Regards.